Mediterr J Rheumatol 2018;29(4):224-7
Study of the incidence of osteoporosis in patients with Sjögren's syndrome (pSS) and investigation of activation of the RANKL / RANK and osteoprotegerin (OPG) system
Authors Information
1. Department of Physiology, School of Medicine, National University of Athens, Athens, Greece
2. Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
  1. Mavragani CP, Moutsopoulos HM. Sjögren syndrome. CMAJ 2014;186(15):E579-86. [https://doi.org/10.1503/cmaj.122037] [PMID: 24566651 ][PMCID: PMC4203623]
  2. Mavragani CP, Moutsopoulos HM. Sjögren’s syndrome. Annu Rev Pathol. 2014;9:273-85. [https://doi.org/10.1146/annurev-pathol-012513-104728] [PMID: 24050623]
  3. Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM. Clinically significant and biopsy-documented renal involvement in primary Sjögren syndrome. Medicine (Baltimore) 2000;79(4):241-9.  [PMID: 10941353]
  4. Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjögren’s syndrome: autoimmune epithelitis. J Autoimmun 2012;39(1-2):34-42. [https://doi.org/10.1016/j.jaut.2011.11.005] [PMID: 22178199] [PMCID: PMC3568660]
  5. Both T, Zillikens MC, Hoorn EJ, Zietse R, van Laar JAM, Dalm VASH, et al. Bone Mineral Density in Sjögren Syndrome Patients with and Without Distal Renal Tubular Acidosis. Calcif Tissue Int 2016;98(6):573-9. [https://doi.org/10.1007/s00223-016-0112-z] [PMID: 26873478] [PMCID: PMC4860192]
  6. Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D, et al. Subclinical atherosclerosis and impaired bone health in patients with primary Sjögren’s syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 2015;17:99. [https://doi.org/10.1186/s13075-015-0613-6] [PMID: 25886059] [PMCID: PMC4416325]
  7. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 2013;19(2):179-92. [https://doi.org/10.1038/nm.3074] [PMID: 23389618]
  8. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008;1143:123-50. [https://doi.org/10.1196/annals.1443.016] [PMID: 19076348]
  9. Danks L, Komatsu N, Guerrini MM, Sawa S, Armaka M, Kollias G, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis 2016;75(6):1187-95. [https://doi.org/10.1136/annrheumdis-2014-207137] [PMID: 26025971]
  10. Liu Z, Xu J, Li H, Zheng Y, He J, Liu H, et al. Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One 2013;8(12):e82453. [https://doi.org/10.1371/journal.pone.0082453]
  11. Xiong J, Piemontese M, Thostenson JD, Weinstein RS, Manolagas SC, O’Brien CA. Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone 2014;66:146-54. [https://doi.org/10.1016/j.bone.2014.06.006] [PMID: 24933342] [PMCID: PMC4125539]
  12. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002;22(4):549-53. [PMID: 11950689]
  13. Poli C, Martin JC, Braudeau C, Bériou G, Hémont C, Charrier C, et al. Receptor activating NF-κB ligand (RANKL) is a constitutive intracellular protein in resting human basophils and is strongly induced on their surface by interleukin 3. Immunobiology 2015;220(5):692-700. [https://doi.org/10.1016/j.imbio.2014.11.009] [PMID: 25433635]
  14. Meednu N, Zhang H, Owen T, Sun W, Wang V, Cistrone C, et al. Production of RANKL by Memory B Cells: A Link Between B Cells and Bone Erosion in Rheumatoid Arthritis. Arthritis Rheumatol 2016;68(4):805-16. [https://doi.org/10.1002/art.39489] [PMID: 26554541] [PMCID: PMC4956406]
  15. Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol 2014;5:511. [https://doi.org/10.3389/fimmu.2014.00511] [PMID: 25368616] [PMCID: PMC4202272]
  16. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 2001;98(9):2784-90. [PMID: 11675352]
  17. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9 Suppl 1:S1. [https://doi.org/10.1186/ar2165] [PMID: 17634140] [PMCID: PMC1924516]
  18. Bonfá AC, Seguro LPC, Caparbo V, Bonfá E, Pereira RMR. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporos Int 2015;26(5):1563-71. [https://doi.org/10.1007/s00198-015-3029-x] [PMID: 25609157]
  19. Park Y-J, Shin Y-J, Kim W-U, Cho C-S. Prediction of subclinical atherosclerosis by serum osteoprotegerin in premenopausal women with systemic lupus erythematous: correlation of osteoprotegerin with monocyte chemotactic protein-1. Lupus 2014;23(3):236-44. [https://doi.org/10.1177/0961203313517151] [PMID: 24531425]
  20. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61(6):554-8. [PMID: 12006334] [PMCID: PMC1754137]